Nephria is in close collaboration with EOFlow and Dr. Yury Gogotsi s lab at Drexel University
PORTMOUTH, N.H., April 29, 2021 /PRNewswire/
On April 29, Nephria Bio, a privately held US corporation specializing in the development of innovative approaches to dialysis, announced that it signed a license agreement with Drexel University to transfer technology of new MXene nanomaterials.
Through this license agreement, Nephria Bio, Inc. ( Nephria Bio ) obtained the exclusive rights to use MXenes, invented and developed by Dr. Yury Gogotsi, PhD, Distinguished University and Bach professor in Drexel s College of Engineering who is a world leader in developing and studying MXenes. Nephria Bio plans to develop more efficient cartridges for dialysis centers and wearable dialysis devices with this technology transfer.
Renishaw helping train, enhance student experience
Renishaw helps develop the next generation of manufacturing professionals with Davis Technical College, Utah.
Renishaw has partnered with
Davis Technical College (Davis Tech), a public technical college in Kaysville, Utah, to provide students with access to the latest in measurement technologies. CNC machining students now have on-site access to coordinate measuring machines (CMMs) and other Renishaw equipment that is helping them to take fast, precise measurements of components.
For over 30 years, Davis Tech has been training and enhancing the lives of its thousands of students as they prepare for a career in the industrial workforce. Through its partnerships, Davis Tech engages industry, educational, and community members to provide shared opportunities for all. Courses found within the program include automation and robotics, CNC machining and manufacturing technology. The range of educational opportunities offered are design
Nephria Bio signs exclusive agreement with Drexel University to license new MXene nanomaterial for future dialysis innovations
News provided by
Share this article
Nephria Bio secures a key technology needed to develop wearable dialysis therapies
Nephria is in close collaboration with EOFlow and Dr. Yury Gogotsi s lab at Drexel University
PORTMOUTH, N.H., April 29, 2021 /PRNewswire/
On April 29, Nephria Bio, a privately held US corporation specializing in the development of innovative approaches to dialysis, announced that it signed a license agreement with Drexel University to transfer technology of new MXene nanomaterials.
Through this license agreement, Nephria Bio, Inc. ( Nephria Bio ) obtained the exclusive rights to use MXenes, invented and developed by Dr. Yury Gogotsi, PhD, Distinguished University and Bach professor in Drexel s College of Engineering who is a world leader in developing and studying MXenes. Nephria Bio plans to develop more efficient cartridges fo
April 29, 2021
MXene materials will be a key element in the production of Nephria Bio s wearable artificial kidney technology
Drexel University’s MXene material is one step closer to transforming the lives of people suffering from end-stage kidney disease. Nephria Bio, Inc., a U.S.-based spin-off of the South Korean medical device company EOFlow Co., Ltd., has signed a licensing agreement with the University to use the two-dimensional material, discovered at Drexel, as a filter in a wearable artificial kidney device it is developing. The technology could allow many of the millions of people suffering from end-stage kidney disease worldwide to move more freely, without spending hours each week anchored to large dialysis machines.